Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
26 avr. 2022 08h30 HE
|
Prothena Corporation plc
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, April 26, 2022 ...
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
28 mars 2022 08h30 HE
|
Prothena Corporation plc
Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc...
Prothena to Participate in Stifel 2022 Virtual CNS Days
21 mars 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
16 mars 2022 05h30 HE
|
Prothena Corporation plc
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to enable...
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
17 févr. 2022 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full year 2021;...
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
10 févr. 2022 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena to Participate in JMP Securities Hematology and Oncology Summit
29 nov. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
04 nov. 2021 16h05 HE
|
Prothena Corporation plc
Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was...
Prothena to Report Third Quarter 2021 Financial Results on November 4th
28 oct. 2021 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 oct. 2021 16h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein...